{
    "2018-05-24": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Is Genome Editing the Next Biotech Breakthrough?",
                "features": {
                    "keywords": [
                        "Genome",
                        "Editing",
                        "Biotech",
                        "Breakthrough"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-05-17",
                "original_text": "FDA Confirms September Action Date for Teva's Migraine Drug",
                "features": {
                    "keywords": [
                        "FDA",
                        "Teva",
                        "Migraine",
                        "Drug",
                        "Action Date"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-04-25",
                "original_text": "Novartis Gets Approval for Remicade Biosimilar in Europe",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Approval",
                        "Remicade",
                        "Biosimilar",
                        "Europe"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-12",
                "original_text": "bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA",
                "features": {
                    "keywords": [
                        "bluebird",
                        "Lenti-D",
                        "Breakthrough",
                        "Therapy",
                        "FDA"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-03-28",
                "original_text": "Noteworthy ETF Inflows: VXUS, NSRGY, NVS, RY",
                "features": {
                    "keywords": [
                        "ETF",
                        "Inflows",
                        "VXUS",
                        "NSRGY",
                        "NVS",
                        "RY"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-07-10",
                "original_text": "Is This Little Biotech the Best Migraine Stock to Buy Now?",
                "features": {
                    "keywords": [
                        "Biotech",
                        "Migraine",
                        "Stock",
                        "Buy"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-25",
                "original_text": "Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for May 25, 2018",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Ex-Dividend",
                        "Date",
                        "JNJ"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-02-15",
                "original_text": "Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings",
                "features": {
                    "keywords": [
                        "Eiger",
                        "Melinta",
                        "Apellis",
                        "Marinus",
                        "Bullish",
                        "Ratings"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            },
            {
                "time": "2018-08-14",
                "original_text": "The Swiss Stock Market Finished Lower After Early Gains Erode",
                "features": {
                    "keywords": [
                        "Swiss",
                        "Stock Market",
                        "Lower",
                        "Gains",
                        "Erode"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}